Below are the most recent publications written about "Hepatitis C" by people in Profiles.
-
Frumento N, Figueroa A, Wang T, Zahid MN, Wang S, Massaccesi G, Stavrakis G, Crowe JE, Flyak AI, Ji H, Ray SC, Shaw GM, Cox AL, Bailey JR. Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency. J Clin Invest. 2022 Aug 01; 132(15).
-
Bozhanova NG, Flyak AI, Brown BP, Ruiz SE, Salas J, Rho S, Bombardi RG, Myers L, Soto C, Bailey JR, Crowe JE, Bjorkman PJ, Meiler J. Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals. Nat Commun. 2022 06 08; 13(1):3178.
-
Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022 Jul 05; 34(7):969-977.e2.
-
Pfaff-Kilgore JM, Davidson E, Kadash-Edmondson K, Hernandez M, Rosenberg E, Chambers R, Castelli M, Clementi N, Mancini N, Bailey JR, Crowe JE, Law M, Doranz BJ. Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening. Cell Rep. 2022 May 24; 39(8):110859.
-
Angelidakis G, Pritchard H, Yibirin M, Jiang Y, Mustafayev K, Torres HA. Impact of CD4+ T-cell count on sustained virologic response to direct-acting antivirals in hepatitis C virus monoinfected cancer patients: a prospective observational study. Diagn Microbiol Infect Dis. 2022 Jul; 103(3):115719.
-
Tunesi S, Dû DL, Gualano G, Millet JP, Skrahin A, Bothamley G, Casas X, Goletti D, Lange C, Musso M, Palmieri F, Pourcher V, Rioux C, Skrahina A, Veziris N, Viatushka D, Jachym-Fréchet M, Guglielmetti L. Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study. J Infect. 2022 06; 84(6):834-872.
-
Mueller PP, Chen Q, Ayer T, Nemutlu GS, Hajjar A, Bethea ED, Peters MLB, Lee BP, Janjua NZ, Kanwal F, Chhatwal J. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. J Hepatol. 2022 Jul; 77(1):55-62.
-
Ogega CO, Skinner NE, Flyak AI, Clark KE, Board NL, Bjorkman PJ, Crowe JE, Cox AL, Ray SC, Bailey JR. B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection. PLoS Pathog. 2022 01; 18(1):e1010179.
-
Kim D, Cholankeril G, Dennis BB, Alshuwaykh O, Kumari R, Wong RJ, Ahmed A. Trends in the Prevalence of Hepatitis C Virus Infection based on the Insurance Status in the United States from 2013 to 2018. Liver Int. 2022 02; 42(2):340-349.
-
Mendlowitz A, Bremner KE, Walker JD, Wong WWL, Feld JJ, Sander B, Jones L, Isaranuwatchai W, Krahn M. Hepatitis C virus infection in First Nations populations in Ontario from 2006 to 2014: a population-based retrospective cohort analysis. CMAJ Open. 2021 Jul-Sep; 9(3):E886-E896.